2015.02.04 - admin Preparation used in 80% of all nuclear medicine procedures will be more readily available as soon as NCBJ POLATOM Radioisotope Centre succeeds to increase its technetium-99m production capacity. NCBJ has just invited potential contractors to submits their offers to built a new 99mTc production line in Świerk.
2014.12.17 - admin Representatives of OECD, IAEA, European Commission, and EURATOM Supply Agency gathered in NCBJ to discuss the role of research reactors in various aspects. The debate was a culmination point of celebrations held on the occasion of the MARIA reactor 40th birthday. Everybody could formulate his/her wishes on the occasion.
2014.12.16 - admin MARIA is a research reactor operated in NCBJ Świerk near Warsaw primarily for physical research and to train staff for nuclear industry and radiation protection needs. It produces also radiopharmaceuticals, special materials/radioactive sources for industry, environment protection and healthcare.
2014.12.04 - admin CERN launched 20.11.2014 its Open Data Portal where data from real collision events produced by the LHC experiments will for the first time be made openly available to all. It is expected that this data will be of high value for the research community, and also be used for education purposes.
2014.12.03 - admin NCBJ experts have designed and developed a continuous-mode source of fast neutrons of energy 14 MeV fed by thermal neutrons produced by the MARIA research reactor in Świerk. Parameters of the reactor-converter combination are good enough to practically use the produced flux of fast neutrons to test various constructional materials necessary to successfully develop 4th generation nuclear reactors and thermonuclear reactors expected to produce majority of energy consumed by mankind in the future. The converter is the sole facility of its kind operated in the world.
2014.12.01 - admin ItraPol and LutaPol, new radiopharmaceutical precursors developed & produced in NCBJ have been awarded in the 17th edition of the “Polish Product of the Future” competition. New drugs produced on the precursors’ basis will help nuclear medicine physicians to more effectively cure metastases and/or to improve quality of life of oncological patients. Drug shipments have already begun.